Search Results - "Suragani, Rajasekhar NVS"

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY by Platzbecker, Uwe, Hayati, Sheida, Ahsan, Aarif, Verma, Amit, Aluri, Srinivas, Rose, Shelonitda, Gandhi, Anita, Nvs Suragani, Rajasekhar, Vodala, Sadanand

Get full text

P459: DISEASE MONITORING OF NPM1‐MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL‐AZA) TREATMENT (TX): A QUAZAR AML‐001 SUBANALYSIS by Lopes De Menezes, Daniel, Roboz, Gail, Döhner, Hartmut, Wei, Andrew, Teresa Voso, Maria, Schuh, Andre, See, Wendy L., Ugidos, Manuel, Amzallag, Arnaud, Risueño, Alberto, H. Eng, Kevin, Nvs Suragani, Rajasekhar, Skikne, Barry, Beach, CL, Prebet, Thomas, Gandhi, Anita

Get full text

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB‐RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS by Jeyaraju, Danny, Hayati, Sheida, Polonskaia, Ann, Browne, Andrew, Risueño, Alberto, Hagner, Patrick, Gupta, Vikas, Talpaz, Moshe, Hernandez, Christopher, Chia, Vincent, Brown, Patrick, De Menezes, Daniel Lopes, La Motte‐Mohs, Ross, Nvs Suragani, Rajasekhar, Gandhi, Anita

Get full text

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML‐001 TRIAL by Lopes De Menezes, Daniel, Wei, Andrew, Döhner, Hartmut, Roboz, Gail, Teresa Voso, Maria, Schuh, Andre, See, Wendy L., Ugidos, Manuel, Amzallag, Arnaud, Risueño, Alberto, Kyriakopoulos, Charalampos, Nvs Suragani, Rajasekhar, Skikne, Barry, Beach, CL, Prebet, Thomas, Gandhi, Anita

Get full text

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY by Aluri, Srinivas, Ahsan, Aarif, Hayati, Sheida, Ugidos, Manuel, Shah, Punit, Lizotte, Kate, Chakraborty, Samarpana, Pradhan, Kith, Sahu, Srabani, Maqbool, Shahina, Shastri, Aditi, Dongre, Ashok, Platzbecker, Uwe, Gandhi, Anita, Nvs Suragani, Rajasekhar, Vodala, Sadanand, Verma, Amit

Get full text

Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes by Verma, Amit, Suragani, Rajasekhar Nvs, Aluri, Srinivas, Shah, Nishi, Bhagat, Tushar D, Alexander, Mark J, Komrokji, Rami, Kumar, Ravi

“…Signaling by the TGF-β superfamily is important in the regulation of hematopoiesis and is dysregulated in myelodysplastic syndromes (MDSs), contributing to…”
Get full text

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial by Jeyaraju, Danny V, Hayati, Sheida, Polonskaia, Ann, Alapa, Maryam, Ugidos, Manuel, Browne, Andrew, Risueño, Alberto, Hagner, Patrick, Gupta, Vikas, Talpaz, Moshe, Hernandez, Christopher, Chia, Vincent, Martin-Regueira, Patricia, Lopes de Menezes, Daniel, La Motte-Mohs, Ross, Suragani, Rajasekhar NVS, Gandhi, Anita K.

Get full text

ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders by Li, Jia, Fredericks, Maureen, Cannell, Marishka, Wang, Kathryn, Sako, Dianne, Maguire, Michelle C, Grenha, Rosa, Liharska, Katia, Krishnan, Lavanya, Bloom, Troy, Belcheva, Elitza P, Martinez, Pedro A, Castonguay, Roselyne, Keates, Sarah, Alexander, Mark J, Choi, Hyunwoo, Grinberg, Asya V, Pearsall, R Scott, Oh, Paul, Kumar, Ravindra, Suragani, Rajasekhar Nvs

“…Patients with neuromuscular disorders suffer from a lack of treatment options for skeletal muscle weakness and disease comorbidities. Here, we introduce as a…”
Get full text

TGFb1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis by Suragani, Rajasekhar NVS, Martinez, Pedro A., Cawley, Sharon M, Li, Robert, Pearsall, Robert Scott, Kumar, Ravindra

“…Introduction: Myelofibrosis (MF) is a clonal stem cell disorder that originates from acquired mutations in the hematopoietic stem cells leading to abnormal…”
Get full text

Rap-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation By Restoring GATA-1 Function in Murine b-Thalassemia by Martinez, Pedro A., Suragani, Rajasekhar NVS, Bhasin, Manoj, Li, Robert, Pearsall, Robert Scott, Kumar, Ravindra

“…We have previously reported that Smad2/3 signaling (of the TGFβ superfamily) is elevated in myelodysplastic syndromes (MDS) and β-thalassemia, diseases that…”
Get full text

Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study by Platzbecker, Uwe, Giagounidis, Aristoteles, Kiewe, Philipp M., Germing, Ulrich, Gotze, Katharina S., Mayer, Karin, Radsak, Markus, Wolff, Thomas, Chromik, Jörg, Reynolds, Joseph, Barron, Carolyn, Rovaldi, Chris, Suragani, Rajasekhar NVS, Zhang, Xiaosha, Laadem, Abderrahmane, Linde, Peter G., Sherman, Matthew L., Oelschlägel, Uta

“…Abstract only…”
Get full text

Modified Actriib-Fc Fusion Protein (ACE-536) Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease by Suragani, Rajasekhar NVS, Li, Robert, Cawley, Sharon M, Pearsall, R. Scott, Kumar, Ravindra

“…Sickle cell disease (SCD) is a debilitating hereditary disorder caused by a single point mutation in the β-globin gene resulting in the production of sickle…”
Get full text

Genetic Investigation of the Role of GDF11 in the Treatment of β-Thalassemia and MDS by Oikonomidou, Paraskevi Rea, La, Ping, Gupta, Ritama, Lo Presti, Vania, Casu, Carla, Breda, Laura, Watson, Deborah, Suragani, Rajasekhar NVS, Kumar, Ravindra, Rivella, Stefano

“…The current treatment of β-thalassemia only partially mitigates the phenotype of the disease, making the need for novel therapeutic agents imperative. The…”
Get full text

Modified Activin Receptor Type IIb-Fc Fusion Protein (RAP-536) Decreases Anemia In a Murine Model Of Myelodysplastic Syndrome and Improves Overall Survival by Suragani, Rajasekhar NVS, Li, Robert, Cawley, Sharon, Pearsall, R. Scott, Kumar, Ravi

“…Myelodysplastic syndromes (MDS) are caused due to abnormal proliferation and differentiation of pluripotent hematopoietic stem cells leading to peripheral…”
Get full text

RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in Myelodysplastic Syndromes by Suragani, Rajasekhar NVS, Mulivor, Aaron, Pearsall, R. Scott, Kumar, Ravindra

“…Abstract 610 Myelodysplatic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis. Patients…”
Get full text

ACE-536 Improves Ineffective Erythropoiesis, Anemia and Co-Morbidities in β-Thalassemia by Suragani, Rajasekhar NVS, Li, Robert, Cawley, Sharon, Rivella, Stefano, Pearsall, R. Scott, Kumar, Ravindra

“…Abstract 248 β-thalassemia, the most common congenital anemia, is caused by mutations in β-globin gene resulting in partial or complete absence of β-globin…”
Get full text

RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in a Murine Model of Myelodysplastic Syndromes by Suragani, Rajasekhar NVS, Li, Robert, Sako, Dianne, Grinberg, Asya, Pearsall, R. Scott, Kumar, Ravindra

“…Abstract 3796 Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by peripheral blood cytopenias such as anemia,…”
Get full text

Haem‐regulated eIF2α kinase is necessary for adaptive gene expression in erythroid precursors under the stress of iron deficiency by Liu, Sijin, Bhattacharya, Sanchita, Han, Anping, Suragani, Rajasekhar N. V. S., Zhao, Wanting, Fry, Rebecca C., Chen, Jane‐Jane

“…Summary Haem‐regulated eIF2α kinase (HRI) is essential for the regulation of globin gene translation and the survival of erythroid precursors in iron/haem…”
Get full text

Oxidative Stress Signaling Pathway of Heme Regulated eIF2α Kinase in mitigating the Severity of β-Thalassemia by Suragani, Rajasekhar NVS, Liu, Sijin, Zhao, Wanting, Chen, Jane-Jane

“…Maturation of erythroid precursors requires active synthesis of hemoglobin which consists of two pairs of α- and β-globin subunits with each monomer bound to a…”
Get full text

RAP-536, A Soluble Activin Receptor Type IIb Murine IgG-Fc Fusion Protein, Prevents Myelodysplastic Syndrome Related Anemia by Mulivor, Aaron, Cadena, Samuel M., Suragani, Rajasekhar NVS, Kumar, Ravindra, Underwood, Kathryn, Seehra, Jas, Pearsall, R. Scott

“…Abstract 978 Myelodysplastic syndrome (MDS) is a premalignant disease characterized by ineffective hematopoiesis. MDS patients can live for extended periods of…”
Get full text